louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05963152: Resistance Exercise and Cognition in People With Type 1 Diabetes
Official title: The Effects of Resistance Exercise on Cognition in People With Type 1 Diabetes: a Randomised Controlled Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: type1diabetes
Keywords: exercise
cognition
Lead sponsor: Dasman Diabetes Institute
Sponsor class: OTHER
First posted: 2023-07-27
Enrollment: 54
Sex: ALL
Minimum age (years): 21
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: 1:1:1 parallel group design
Primary purpose: BASIC_SCIENCE

Brief summary: The aim of the current study is to determine the effects of resistance exercise on performance of the Paced Auditory Serial Addition Test and the Colour Trails Test.


Eligibility criteria: Inclusion Criteria:

* Physician confirmed type 1 diabetes for at least 1 year
* Stable insulin therapy for 3 months prior to the study

Exclusion Criteria:

* BMI of 45 or higher
* BP of 160/100mmHg or higher
* autonomic neuropathy
* severe proliferative retinopathy
* joint or limb injuries preventing weight-bearing activity
* autonomic neuropathy
* severe proliferative retinopathy
* any other medical condition that prevents participants from exercising safely.

Primary outcomes:
measure: Chronic change in Paced Auditory Serial Addition Test (PASAT) score
timeFrame: Change from baseline to 12 weeks
measure: Chronic change in Colour Trails Test score
timeFrame: Change from baseline to 12 weeks
Secondary outcomes:
measure: Baseline acute change in Paced Auditory Serial Addition Test (PASAT) score
timeFrame: Change from before (0 hour) to 1 hour post exercise during week 1
measure: 12 week acute change in Paced Auditory Serial Addition Test (PASAT) score
timeFrame: Change from before (0 hour) to 1 hour post exercise during week 12
measure: Baseline acute change in Colour Trails Test score
timeFrame: Change from before (0 hour) to 1 hour post exercise during week 1
measure: 12 week acute change in Colour Trails Test score
timeFrame: Change from before (0 hour) to 1 hour post exercise during week 12
Other outcomes:
Locations:
city: Kuwait City
country: Kuwait
facility: Dasman Diabetes Institute
Study officials:
References:
Clinical trial NCT02992652: Allopurinol in Prevention of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis
Official title: Role of Allopurinol in Prevention of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Endoscopic Retrograde Cholangiopancreatography
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2016-12-14
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: * The investigators evaluated the role of allopurinol in prevention of post-ERCP pancreatitis.
* 100 Egyptian patients who were candidates for ERCP were included and divided into two groups. Group 1 (study group) included 50 patients who received two doses of allopurinol 300 mg each, 15 hours and 3 hours before ERCP and Group 2 (control group) included 50 patients who did not receive allopurinol prophylaxis.

Detailed description: A diagnosis of procedure-related pancreatitis was based on an increased serum amylase level greater than three times the upper normal limits, associated with abdominal pain requiring analgesics and persisting for at least 24 hours after the procedure.

Eligibility criteria: Inclusion Criteria:

* Patients who were going to be subjected to ERCP due to different causes

Exclusion Criteria:

* Patients with clinically evident acute pancreatitis or hyperamylesemia (≥150 IU/L) before the procedure.
* Current or recent use of allopurinol (within the last 48 hours).
* Hypersensitivity to allopurinol or hydro-soluble contrast solutions.
* Current use of drugs with a known interaction with allopurinol, including cyclophosphamide, chlorpropamide, azathioprine, mercaptopurines, or probenecid.
* NSAIDS intake within a week prior to assessment.
* Previous endoscopic or surgical sphincterotomy.
* Those with severe co-morbid conditions.
* Female patients with a known or suspected pregnancy and/or lactation.

Primary outcomes:
measure: Diagnosis of procedure-related pancreatitis
timeFrame: At least 24 hours after the ERCP
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03937752: 3D Endoanal Ultrasound and Anal Fistula
Official title: The Role of 3D Endoanal Ultrasound in Management of Anal Fistulas
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Anal Fistula
Keywords: anal fistula
fistula in ano
endoanal ultrasound
3D ultrasound
3D ultrasonography
endoanal ultrasonography
diagnostics
Lead sponsor: Region Skane
Sponsor class: OTHER
First posted: 2019-05-06
Enrollment: 95
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with newly diagnosed anal fistula with no previous anal fistula procedures.

Brief summary: The study aims to evaluate the use of 3D endoanal ultrasound in preoperative management of anal fistula disease.


Eligibility criteria: Inclusion Criteria:

* anal fistula
* no previous fistula procedures

Exclusion Criteria:

* previous fistula procedures
* ano/rectovaginal fistula
* inflammatory bowel disease
* more than one internal openings

Primary outcomes:
measure: Fistula position
timeFrame: Day 1
measure: Fistula level
timeFrame: Day 1
measure: Fistula length
timeFrame: Day 1
Secondary outcomes:
Other outcomes:
Locations:
city: Malmö
country: Sweden
facility: Pelvic Floor Centre
Study officials:
affiliation: Region Skane
name: Ursula Aho Fält, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01658852: Effects and Safety of Metronidazole in Patients With Gastrectomy
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE3
Conditions: Post Gastrectomy State
Lead sponsor: The Catholic University of Korea
Sponsor class: OTHER
First posted: 2012-08-07
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Recent study showed that SIBO is common among postgastrectomy patients and It appears to be associated with postprandial intestinal symptoms and might aggravate late hypoglycemia. SIBO could be a new therapeutic target for managing intestinal symptoms in postgastrectomy patients.The purpose of this study is to determine whether antiboitic (metronidazole) is effective in patients with postgasrectomy syndrome


Eligibility criteria: Inclusion Criteria:

* age between 18 and 70
* gastrectomy for early gastric cancer with complete resection
* no reccurrence after follow up more than 6 months
* identified small bowel bacterial overgrowth by hydrogen breath test
* symptoms of postgastrectomy syndrome

Exclusion Criteria:

* hypersensive to metronidazole
* systemic chemotherapy history
* other organic gastrointestinal disease (inflammatory bowel disease, carcinoid syndrome, amyloidosis, intestinal obstruction)
* other gastrointestinal operation history except appendectomy, cholecystectomy)
* recent colonoscopic examination (within 30 days)
* uncontrolled psychopathy
* drug or alcohol abuser
* pregnant or breast feeding woman
* recent history of antibiotics treatment (within 90 days)
* recent history of PPI or H2 blocker treatment (within 30 dyas)
* recent history of probiotics treatment (within 30 dyas)
* recent history of prokinetics or antispasmotic treatment (within 15 days)
* severe systemic illness

Primary outcomes:
measure: Patient's Global Assessment of abdominal symptom
timeFrame: 4 week
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00640952: Acamprosate for Treatment of Compulsive Behaviors and Craving in Parkinson's Disease
Official title: Acamprosate for Treatment of Compulsive Behaviors and Craving in Parkinson's Disease
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Parkinson's Disease
Keywords: Parkinson's disease
impulse control behaviors
dopa-dysregulation
Lead sponsor: Baylor College of Medicine
Sponsor class: OTHER
Collaborators: name: National Parkinson Foundation
First posted: 2008-03-21
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine how many patients with Parkinson's disease have compulsive behaviors, and what types of behaviors they have. This study will also determine if acamprosate can be used to treat compulsive behaviors in Parkinson's disease patients.


Eligibility criteria: Inclusion Criteria:

1. Idiopathic Parkinson's disease
2. Active dopaminergic therapy at stable dose for one month (levodopa or dopamine agonist)
3. Able and willing to complete Rating Scales
4. Presence of one or more compulsive behavior based on responses to Rating Scales (defined as \>5 on the SOGS; \>17 on the YBOCS-SV and YBOCS-CUV; \>1.7 on the SCS for women and \>2.1 on the SCS for men; \>15 on the YBOCS-BE, \>5.5 on the CQ).
5. Written informed consent

Inclusion criteria (controls):

1. No significant psychiatric disease
2. Able and willing to complete Rating Scales
3. Written informed consent

Exclusion Criteria:

1. No anticipated need for adjustment of medications for Parkinson's disease
2. Current participation in another clinical study
3. History of unstable psychiatric disease (as determined by the Principal Investigator)
4. Women of childbearing age not using appropriate contraceptive methods (oral contraceptives, condoms, surgery)

Primary outcomes:
measure: safety and efficacy compared to baseline scores
timeFrame: 6 months
Secondary outcomes:
measure: change from baseline assessment tools used in the study
timeFrame: 6 months
Other outcomes:
Locations:
city: Houston
country: United States
facility: PDCMDC 6550 Fannin, Suite 1801
state: Texas
Study officials:
affiliation: Baylor College of Medicine
name: Joohi Jimenez-Shahed, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02373852: PMS Retrospective Study of WIRION Performance in Patients Undergoing Saphenous Vein Graft (SVG) Intervention
Official title: Post Marketing Surveillance (PMS) Retrospective Study of WIRION Performance in Patients Undergoing Saphenous Vein Graft (SVG) Intervention
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Stenosis
Lead sponsor: Gardia Medical
Sponsor class: INDUSTRY
First posted: 2015-02-27
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients undergoing percutaneous intervention (PI) of saphenous vein graft (SVG) stenting

Brief summary: The objective of this study is to collect data on the use of the WIRION system in Patients undergoing Percutaneous Intervention of Saphenous Vein Graft (SVG).

Detailed description: WIRION system is used as protection device in patients undergoing SVG stenting procedure. This retrospective study collects data on the usability of the WIRION during the procedure.

Eligibility criteria: Inclusion Criteria:

* Patients underwent percutaneous intervention (PI) of SVG stenting in which the WIRIONTM system was used.
* Patient is greater than or equal to 18 years of age.

Exclusion Criteria:

* Undergone cardiac surgery in the past 60 days before the procedure.

Primary outcomes:
measure: Number of Participants With Adverse Events During the Procedure and up to 30 Days Following Procedure
timeFrame: 30 Days
measure: Number of Patients That Undergo Successful SVG Procedure
timeFrame: 30 Days
Secondary outcomes:
Other outcomes:
Locations:
city: Haifa
country: Israel
facility: Bnai Zion
Study officials:
affiliation: Gardia medical manufacture the WIRION used in the study
name: Vardit Segal, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT02636452: Cardiopulmonary Exercise Testing in Interstitial Lung Disease
Official title: Cardiopulmonary Exercise Testing in Interstitial Lung Disease
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Interstitial Lung Disease
Lead sponsor: Wissenschaftliches Institut Bethanien e.V
Sponsor class: OTHER
Collaborators: name: Roche Pharma AG
First posted: 2015-12-21
Enrollment: 58
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients with Interstitial lung diseases

Brief summary: In patients with Interstitial lung diseases (ILD) dyspnea is the most often symptom. Pulmonary lung function tests often do not Show the dyspnea. Aim of the study is to evaluate cardiopulmonary exercise testing concerning therapeutic Monitoring in ILD.


Eligibility criteria: Inclusion Criteria:

* informed consent provided
* ILD

Exclusion Criteria:

* no informed consent
* no ILD

Primary outcomes:
measure: Alveolar-arterial oxygen partial pressure difference (AaDO2) in cardipulmonary exercise testing in ILD
timeFrame: quarterly, three years
Secondary outcomes:
Other outcomes:
Locations:
city: Solingen
country: Germany
facility: Bethanien Hospital, Clinic for Pneumology and Allergology, Center for Sleep and Respiratory Medicine
state: NRW
Study officials:
References:
citation: Fischer A, West SG, Swigris JJ, Brown KK, du Bois RM. Connective tissue disease-associated interstitial lung disease: a call for clarification. Chest. 2010 Aug;138(2):251-6. doi: 10.1378/chest.10-0194.
citation: Fell CD, Liu LX, Motika C, Kazerooni EA, Gross BH, Travis WD, Colby TV, Murray S, Toews GB, Martinez FJ, Flaherty KR. The prognostic value of cardiopulmonary exercise testing in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2009 Mar 1;179(5):402-7. doi: 10.1164/rccm.200802-241OC. Epub 2008 Dec 12.
citation: Hagmeyer L, Herkenrath S, Anduleit N, Treml M, Randerath W. Cardiopulmonary Exercise Testing Allows Discrimination Between Idiopathic Non-specific Interstitial Pneumonia and Idiopathic Pulmonary Fibrosis in Mild to Moderate Stages of the Disease. Lung. 2019 Dec;197(6):721-726. doi: 10.1007/s00408-019-00282-9. Epub 2019 Nov 1.
Clinical trial NCT00898352: Radiation Therapy or Surgery in Treating Patients With Previously Untreated Vulva Cancer With Positive Groin Lymph Nodes
Official title: Phase III Radiation Therapy vs Pelvic Node Resection for Previously Untreated Invasive Squamous Cell Carcinoma of the Vulva With Positive Groin Nodes
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Vulvar Cancer
Keywords: stage III vulvar cancer
squamous cell carcinoma of the vulva
Lead sponsor: GOG Foundation
Sponsor class: NETWORK
Collaborators: name: National Cancer Institute (NCI)
First posted: 2009-05-12
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Primary purpose: TREATMENT

Brief summary: RATIONALE: Patient abstract not available

PURPOSE: Patient abstract not available

Detailed description: OBJECTIVES: I. Compare the efficacy of pelvic node resection vs. bilateral groin and pelvic node irradiation for invasive squamous cell carcinoma of the vulva in patients having positive groin nodes.

OUTLINE: Randomized study. Arm I: Surgery. Deep pelvic node dissection on sides containing positive nodes only. Arm II: Radiotherapy. Megavoltage (1 MeV or greater) to bilateral groin and pelvic nodes.

PROJECTED ACCRUAL: Anticipated annual accrual is approximately 200 patients, with an active phase estimated at 2.5-3 years. Protocol closed July 1984.

Eligibility criteria: DISEASE CHARACTERISTICS: See General Eligibility Criteria

PATIENT CHARACTERISTICS: See General Eligibility Criteria

Primary outcomes:
measure: Recurrence rate
measure: Survival rate
measure: Subjective status on GOG performance scale
measure: Time to recurrence
measure: Survival time
measure: Morbidity of treatment
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Sidney Kimmel Cancer Center at Thomas Jefferson University
name: George C. Lewis, MD
role: STUDY_CHAIR
References:
citation: Kunos C, Simpkins F, Gibbons H, Tian C, Homesley H. Radiation therapy compared with pelvic node resection for node-positive vulvar cancer: a randomized controlled trial. Obstet Gynecol. 2009 Sep;114(3):537-546. doi: 10.1097/AOG.0b013e3181b12f99.
citation: Homesley HD, Bundy BN, Sedlis A, Adcock L. Radiation therapy versus pelvic node resection for carcinoma of the vulva with positive groin nodes. Obstet Gynecol. 1986 Dec;68(6):733-40.
Clinical trial NCT04676152: Validation of Noninvasive Blood Pressure Device
Official title: Validation of Noninvasive Blood Pressure Device
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Hypertension
Hypotension
Lead sponsor: Masimo Corporation
Sponsor class: INDUSTRY
First posted: 2020-12-19
Enrollment: 106
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: This is a prospective, nonrandomized multi-center study for the investigation of noninvasive sphygmomanometers.

The purpose of the study is to validate the clinical performance of the Masimo noninvasive blood pressure device compared to reference auscultatory measurements.


Eligibility criteria: Inclusion Criteria:

* Age 18 years and older
* Site 1; Stage 1 only: Subjects with a history of hypertension (\> 140/85 mmHg) or hypotension (\< 100/60 mmHg) within the last 3 months. Stage 2 only: No criterion for blood pressure
* Site 2; Stage 1 and 2: Subjects with systolic blood pressure \< 140/90 mmHg.
* Ability to provide informed consent

Exclusion Criteria:

* Febrile subjects
* Subjects displaying respiratory symptoms, or with suspected respiratory illness
* Subjects whose skin is not intact, e.g. wounded, in or at the vicinity of the cuff placement site
* Subjects with removed axillary lymph nodes or mastectomies
* Subjects with peripheral artery disease
* Pregnant women (patient reported)
* Subjects deemed not suitable for the study at the discretion of the investigator

Primary outcomes:
measure: Mean and Standard Deviation of Differences Between Masimo NIBP Device and Manual Sphygmomanometer Measurements.
timeFrame: 1 hour
Secondary outcomes:
Other outcomes:
Locations:
city: Irvine
country: United States
facility: Site 2
state: California
city: Lomita
country: United States
facility: Site 1
state: California
Study officials:
References:
Clinical trial NCT02835352: Essential Oils on Anxiety of Patients Suffering From Cancer
Official title: Impact of Essential Oils on Anxiety of Patients Suffering From Metastasis Cancer - Feasibility Study
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Neoplasm Metastasis
Keywords: anxiety
Lead sponsor: Center Eugene Marquis
Sponsor class: OTHER
First posted: 2016-07-18
Enrollment: 29
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: This study evaluates the impact of essential oils massage on anxiety of patients who are suffering from cancer at a metastasis stage. Half of patients will be massaged first by essential oils and then by oil only. The other half will be massaged first by oil and then by essential oils.


Eligibility criteria: Inclusion Criteria:

* Adult suffering from cancer at a metastatic stage
* Life expectancy \> 15 days, assessed by investigator
* Hospitalized at the Chevrel unit from Centre Eugène Marquis, palliative unit care, for more than 15 days
* Regular anxiolytic treatment or imperative need to introduce anxiolytic treatment (assessed by investigator) within 48 hours following his hospitalization entry
* \> 18 years

Exclusion Criteria:

* Patient already recruited in a therapeutic trial
* Patient not covered by a social security system
* Pregnant or likely pregnant patient, breastfeeding patient
* Allergy to any component of essential oils mixture and vegetable oils : bitter orange petitgrain, fine lavender, ylang-ylang, macadamia
* Minors, people deprived of their liberty or protected people,
* Impaired cognitive functions making impossible to obtain informed consent

Primary outcomes:
measure: Anxiolytic consumption
timeFrame: 7 days
Secondary outcomes:
Other outcomes:
Locations:
city: Rennes
country: France
facility: Centre Eugène Marquis
Study officials:
affiliation: Centre Eugène Marquis
name: Agnès Hutin, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01272752: Anti-psychotic Medication (New Use) Weight Loss Study
Official title: Surveillance Study of Weight Response and Body Composition in Subjects Who Are First-Time Users (Less Than 3 Months) of the Following Medications: Risperdal, Seroquel, and/or Zyprexa, in Combination With 500 mg IHBG-10 TID
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
Conditions: Obesity
Keywords: obesity
weight loss
weight management
anti-psychotic medication
nutriceutical
Lead sponsor: Avera McKennan Hospital & University Health Center
Sponsor class: OTHER
First posted: 2011-01-10
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a pilot study to determine the safety and efficacy of an investigational product (IHBG-10) on weight change and changes in body composition in subjects who have just started taking (for less than three months) certain anti-psychotic medications (Risperdal, Seroquel, and/or Zyprexa).

Detailed description: A total of 30 subjects will be enrolled in this study. They will be randomized in to one of two groups. One group (of 20 subjects) will take 500 mg of the investigational product (IHBG-10) 15 minutes prior to the three main meals of the day; subjects will continue to take their prescribed anti-psychotic medications. The other group (of 10 subjects) will take a placebo 15 minutes prior to the three main meals of the day; subjects will continue to take their prescribed anti-psychotic medications. Subjects will take the investigational product or placebo for 12 weeks. Participation in this study involves 4 study visits.

Eligibility criteria: Inclusion Criteria:

* Men and women, age 18 and older
* Agree to keep diet, exercise and all current health habits stable during participation in the study
* Have been taking Risperdal (Risperidone), Seroquel (Quetiapine), or Zyprexa (Olanzapine) for less than 3 months

Exclusion Criteria:

* Current active acute psychotic episode
* Women who are pregnant, breastfeeding or planning to become pregnant
* Prior bariatric surgery
* Use of prescription or over-the-counter appetite suppressants, herbal products or other medications for weight loss within the past month
* Obesity as a result of a clinically-diagnosed endocrine problem

Primary outcomes:
measure: Weight
timeFrame: 12 weeks
Secondary outcomes:
measure: Body composition
timeFrame: 12 weeks
Other outcomes:
Locations:
city: Sioux Falls
country: United States
facility: Avera Research Institute
state: South Dakota
Study officials:
affiliation: Avera McKennan Hospital & University Health Center
name: Timothy Soundy, MD
role: PRINCIPAL_INVESTIGATOR
References: